The two major aspects of my role cover different ends of the early drug discovery & development pipeline. The first is to design the biomarker and patient segmentation strategies for drug discovery projects, and the second is to discover new mechanisms and targets for our key disease areas, leading to the initiation of new drug discovery projects. I am the Translational Science Lead on three projects ranging in stage from pre-clinical up to Phase 2 clinical development, and in addition I lead several academic collaborations addressing target discovery, new mechanisms and patient segmentation in the areas of asthma and COPD.